Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 19, 2026, 1:13 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 112 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Omalizumab Clear all
Completed Phase 3 Interventional Results available

Omalizumab as Monotherapy and as Adjunct Therapy to Multi-Allergen OIT in Food Allergic Participants

NCT03881696
View directory record Official record
Conditions
Peanut Allergy, Multi-food Allergy
Interventions
Omalizumab, Placebo for Omalizumab, Multi-Allergen Oral Immunotherapy, Placebo for Multi-Allergen Oral Immunotherapy, Double-Blind Placebo-Controlled Food Challenge Based Treatment
Drug · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
1 Year to 55 Years
Enrollment
458 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
10
States / cities
Little Rock, Arkansas • Stanford, California • Denver, Colorado + 7 more
Source: ClinicalTrials.gov public record
Updated Sep 22, 2026 · Synced Oct 19, 2026, 1:13 PM EDT
Completed Phase 2 Interventional Results available

A Randomized, Double-Blind, Placebo-Controlled Study of Omalizumab for Idiopathic Anaphylaxis

NCT00890162
View directory record Official record
Conditions
Anaphylaxis, Hypotension, Bronchospasm, Angioedema
Interventions
Epinephrine, Omalizumab (Xolair), Placebos
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 70 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2019
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 1, 2019 · Synced Oct 19, 2026, 1:13 PM EDT
Completed No phase listed Observational Results available

Pharmacosurveillance Data Repository of Patients With and Without History of Anaphylactic Reactions Subsequent to Xolair Dosing

NCT00813748
View directory record Official record
Conditions
Allergic Asthma
Interventions
Xolair
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
Not listed
Enrollment
118 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
7
States / cities
Los Angeles, California • Valrico, Florida • Hinsdale, Illinois + 4 more
Source: ClinicalTrials.gov public record
Updated Jul 11, 2017 · Synced Oct 19, 2026, 1:13 PM EDT
Completed Early Phase 1 Interventional

Xolair Treatment for Milk Allergic Children

NCT00968110
View directory record Official record
Conditions
Milk Allergy
Interventions
omalizumab
Drug
Lead sponsor
Boston Children's Hospital
Other
Eligibility
4 Years to 18 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2017
U.S. locations
2
States / cities
Stanford, California • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 2, 2018 · Synced Oct 19, 2026, 1:13 PM EDT
Completed Phase 2 Interventional Results available

Study to Evaluate Tezepelumab in Adults With Chronic Spontaneous Urticaria

NCT04833855
View directory record Official record
Conditions
Chronic Spontaneous Urticaria
Interventions
Tezepelumab Dose 1, Tezepelumab Dose 2, Omalizumab, Placebo
Biological
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 80 Years
Enrollment
183 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
25
States / cities
Birmingham, Alabama • Fountain Valley, California • Laguna Niguel, California + 21 more
Source: ClinicalTrials.gov public record
Updated Apr 9, 2025 · Synced Oct 19, 2026, 1:13 PM EDT
Withdrawn Phase 3 Interventional

Efficacy and Safety of Rituximab Combined With Omalizumab in Patients With Bullous Pemphigoid

NCT04128176
View directory record Official record
Conditions
Bullous Pemphigoid
Interventions
Rituximab combined with Omalizumab
Drug
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years to 90 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Jul 3, 2024 · Synced Oct 19, 2026, 1:13 PM EDT
Completed No phase listed Observational

A Study About the Use of Omalizumab in the Treatment of Food Allergy and Anaphylaxis

NCT07027163
View directory record Official record
Conditions
Food Hypersensitivity, Anaphylaxis
Interventions
Not listed
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
6 Years and older
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
1
States / cities
East Hanover, New Jersey
Source: ClinicalTrials.gov public record
Updated Jun 18, 2025 · Synced Oct 19, 2026, 1:13 PM EDT
Completed Phase 2 Interventional Results available

OIT and Xolair® (Omalizumab) in Cow's Milk Allergy

NCT01157117
View directory record Official record
Conditions
Milk Allergy
Interventions
Placebo for omalizumab, Omalizumab, Milk powder
Biological · Drug
Lead sponsor
Hugh A Sampson, MD
Other
Eligibility
7 Years to 35 Years
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
3
States / cities
Stanford, California • Baltimore, Maryland • New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 14, 2020 · Synced Oct 19, 2026, 1:13 PM EDT
Completed Phase 2 Interventional Results available

Multi Immunotherapy to Test Tolerance and Xolair

NCT02626611
View directory record Official record
Conditions
Food Allergy
Interventions
Omalizumab, Food Flour Buildup
Drug
Lead sponsor
Kari Christine Nadeau
Other
Eligibility
4 Years to 55 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
7
States / cities
Los Angeles, California • Mountain View, California • Chicago, Illinois + 4 more
Source: ClinicalTrials.gov public record
Updated Dec 18, 2017 · Synced Oct 19, 2026, 1:13 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Phase 1, Randomized, Placebo-controlled, Dose-escalation Safety Study of MEDI4212 in Subjects With IgE >= 30 IU/mL

NCT01544348
View directory record Official record
Conditions
Allergic Asthma, Atopic Dermatitis, Allergic Rhinitis, Healthy Volunteers
Interventions
Placebo, Omalizumab, MEDI4212 5 mg Subcutaneous, MEDI4212 15 mg Subcutaneous, MEDI4212 60 mg Subcutaneous, MEDI4212 150 mg Subcutaneous, MEDI4212 300 mg Subcutaneous, MEDI4212 300 mg Intravenous
Other · Biological
Lead sponsor
MedImmune LLC
Industry
Eligibility
18 Years to 60 Years
Enrollment
295 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
7
States / cities
Cypress, California • Glendale, California • Denver, Colorado + 4 more
Source: ClinicalTrials.gov public record
Updated Dec 30, 2014 · Synced Oct 19, 2026, 1:13 PM EDT
Withdrawn Phase 4 Interventional

Sustained Effect of Urticaria Remission With Relatively High Dose Vitamin D Supplementation After Omalizumab Discontinuation

NCT02742805
View directory record Official record
Conditions
Urticaria
Interventions
Vitamin D (4,000 IU/day), Vitamin D (400 IU/day), Omalizumab
Dietary Supplement · Drug
Lead sponsor
Selina Gierer, D.O.
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated May 1, 2018 · Synced Oct 19, 2026, 1:13 PM EDT
Completed Phase 4 Interventional Results available

Evaluate the Effect of Omalizumab on Markers of Asthma Impairment in Patients With Persistent Allergic Asthma

NCT00870584
View directory record Official record
Conditions
Persistent Allergic Asthma
Interventions
Omalizumab, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
12 Years and older
Enrollment
271 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
50
States / cities
Jasper, Alabama • Anchorage, Alaska • Scottsdale, Arizona + 46 more
Source: ClinicalTrials.gov public record
Updated Nov 17, 2011 · Synced Oct 19, 2026, 1:13 PM EDT
Completed Phase 2 Interventional Results available

Treatment With Omalizumab to Improve the Asthmatic Response to Rhinovirus Experimental Infection With Rhinovirus

NCT02388997
View directory record Official record
Conditions
Asthma
Interventions
omalizumab, Rhinovirus (strain 16)
Drug · Biological
Lead sponsor
University of Virginia
Other
Eligibility
18 Years to 40 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Jul 9, 2018 · Synced Oct 19, 2026, 1:13 PM EDT
Terminated Phase 4 Interventional Results available

Sputum-derived Cellular Targets After Xolair (Omalizumab)

NCT02658877
View directory record Official record
Conditions
Asthma
Interventions
Omalizumab, Placebo
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 65 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 30, 2019 · Synced Oct 19, 2026, 1:13 PM EDT
Completed Phase 4 Interventional Results available

Study to Evaluate the Effect of Omalizumab on Improving the Tolerability of Specific Immunotherapy in Patients With Persistent Allergic Asthma

NCT00267202
View directory record Official record
Conditions
Allergic Asthma
Interventions
Placebo, Omalizumab, Immunotherapy
Drug
Lead sponsor
Novartis
Industry
Eligibility
18 Years to 55 Years
Enrollment
275 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
East Hanover, New Jersey
Source: ClinicalTrials.gov public record
Updated Sep 14, 2016 · Synced Oct 19, 2026, 1:13 PM EDT
Completed Phase 4 Interventional Results available

Inner-City Anti-IgE Therapy for Asthma

NCT00377572
View directory record Official record
Conditions
Asthma
Interventions
omalizumab, omalizumab placebo
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
6 Years to 20 Years
Enrollment
419 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
8
States / cities
Tucson, Arizona • Denver, Colorado • Washington D.C., District of Columbia + 5 more
Source: ClinicalTrials.gov public record
Updated Mar 21, 2017 · Synced Oct 19, 2026, 1:13 PM EDT
Completed Phase 1 Interventional

Omalizumab With Oral Food Immunotherapy With Food Allergies Open Label Safety Study in a Single Center

NCT01510626
View directory record Official record
Conditions
Immune System Diseases
Interventions
Food proteins, Omalizumab
Dietary Supplement · Drug
Lead sponsor
Stanford University
Other
Eligibility
4 Years to 55 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Dec 10, 2015 · Synced Oct 19, 2026, 1:13 PM EDT
Completed No phase listed Observational

XOLAIR (Omalizumab) Outcomes in Pediatric Allergic Asthma Patients in the United States

NCT05157087
View directory record Official record
Conditions
Asthma
Interventions
Omalizumab
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
6 Years to 11 Years
Enrollment
16,246 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
East Hanover, New Jersey
Source: ClinicalTrials.gov public record
Updated Dec 16, 2021 · Synced Oct 19, 2026, 1:13 PM EDT
Completed Phase 1 Interventional

Single Center Study Using Omalizumab in Subjects With Atopic Dermatitis

NCT01678092
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
omalizumab
Biological
Lead sponsor
Stanford University
Other
Eligibility
4 Years to 25 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Nov 26, 2015 · Synced Oct 19, 2026, 1:13 PM EDT
Terminated Phase 4 Interventional Results available

A Study to Assess the Impact of Omalizumab on Exercise Capacity, Physical Activity, and Sleep Quality in Participants With Moderate to Severe Allergic Asthma

NCT04195958
View directory record Official record
Conditions
Moderate-to-severe Allergic Asthma
Interventions
Omalizumab
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
12
States / cities
Rolling Hills Estates, California • Denver, Colorado • Pembroke Pines, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Mar 15, 2022 · Synced Oct 19, 2026, 1:13 PM EDT
Completed No phase listed Observational

An Observational Study of the Use and Safety of Xolair® During Pregnancy

NCT00373061
View directory record Official record
Conditions
Asthma
Interventions
Xolair®
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
Female only
Enrollment
309 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2018
U.S. locations
1
States / cities
Morrisville, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 14, 2018 · Synced Oct 19, 2026, 1:13 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

The Effects of Omalizumab (Anti-IgE) on the Late-phase Response to Nasal Allergen Challenge

NCT01003301
View directory record Official record
Conditions
Cat Allergy
Interventions
Omalizumab, Placebo
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 50 Years
Enrollment
19 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2013
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 7, 2014 · Synced Oct 19, 2026, 1:13 PM EDT
Terminated Not applicable Interventional

Soluble CD23 Expression in Asthma Patients Treated With OMA

NCT00226200
View directory record Official record
Conditions
Asthma
Interventions
Omalizumab
Drug
Lead sponsor
University of Mississippi Medical Center
Other
Eligibility
18 Years to 64 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
1
States / cities
Jackson, Mississippi
Source: ClinicalTrials.gov public record
Updated Dec 1, 2008 · Synced Oct 19, 2026, 1:13 PM EDT
Completed Phase 4 Interventional Results available

EValuating trEatment RESponses of Dupilumab Versus Omalizumab in Type 2 Patients

NCT04998604
View directory record Official record
Conditions
Chronic Rhinosinusitis With Nasal Polyps, Asthma
Interventions
Dupilumab, Omalizumab, Placebo
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
360 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
16
States / cities
Los Angeles, California • Tampa, Florida • Chicago, Illinois + 12 more
Source: ClinicalTrials.gov public record
Updated Oct 23, 2025 · Synced Oct 19, 2026, 1:13 PM EDT